A c c e p t e d M a n u s c r i p t 3 remodeling resulting in the disruption of cell-cell contacts, paracellular gap formation and EC barrier compromise. 3, 4 Apart from ventilation strategies there is no standard treatment for pulmonary edema, making the investigation of regulatory mechanisms of endothelial barrier dysfunction highly clinically important.
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Endothelial barrier properties. The vascular endothelium serves as a semi-selective barrier lining in the vessel walls ( Fig. 1) . It dynamically regulates the liquid and macromolecule transport between the blood and the interstitial space. 10 The vasculature is lined by heterogeneous population of endothelial cells. This heterogeneity is derived from the origin of endothelial cells in the vascular tree. The barrier function, surface biochemistry, and morphology of confluent monolayers of microvascular and macrovascular endothelial cells are different for these two cell types. 11 In general, microvascular EC form a tighter barrier, compared to macrovascular one. It was found that permeability is ~16-fold less for sucrose and to 2-fold less for albumin in microvascular EC compared to macrovascular EC monolayers. 12 Conversely, primary cultures of microvascular EC produced 10 times higher transmonolayer electrical resistance (TER) compared to macrovascular one. 13 Although the precise mechanisms that regulate this variability are still under investigation, microarray analysis showed a significant variation in microvascular and macrovascular gene expression patterns.
14 Extracellular matrix proteins, collagen 4α1, collagen 4α2, and laminin were associated with microvessel endothelia, while fibronectin, collagen 5α1, and collagen 5α2
were seen with the large vessel endothelia. 14 Furthermore, electron microscopy revealed that microvascular EC have more developed intercellular junctions with more focal membrane adhesion sites per junction than the macrovascular cells. 12 Pulmonary artery endothelial cells (macrovascular EC) participate in blood homeostasis, blood-tissue exchange regulation under various conditions. 15 They share similarities in cell characteristics and in physiological properties with pulmonary microvascular EC. However, in vivo models of pulmonary edema A c c e p t e d M a n u s c r i p t 4 suggest that most fluid filtration occurs in the microcirculation. 16 Endothelial permeability pathways. A variety of physical, inflammatory and bioactive stimuli alter the EC barrier leading to gap formation, increasing vessel permeability and compromising organ function. Permeability across endothelial and epithelial cell monolayers can involve transcellular, paracellular or the combination of both pathways (Fig. 2) . The transcellular transport involves membrane-attached cytosolic caveolae that migrate through the endothelial cells and transfer macromolecules from the blood to the interstitium. 10 The main player in this process is the Src kinase, which can phosphorylate caveolin-1 on tyrosine residues inducing the migration of the vesicles across the endothelium. 17 Recent studies demonstrated that transcellular permeability increase precedes and may trigger paracellular permeability increase via signaling involved Src-mediated phosphorylation of caveolin-1.
18
However, majority of trafficking occurs through the paracellular route, 19 which will be described in this review in more details.
External stimuli leading to EC barrier compromise. The capillary endothelium is impermeable to macromolecules under basal conditions. This is due to the network of cytoskeletal and cell-junction elements which protect the endothelial barrier integrity. In state of acute or chronic inflammation, sepsis, diabetes, angiogenesis, or excessive level of mechanical alterations (stretch or shear stress), the EC barrier integrity is compromised.
Inflammatory mediators such as LPS, thrombin, pro-inflammatory cytokines, or reactive oxygen species induce the loss of endothelial barrier function leading to permeability increase to solute and plasma proteins. [20] [21] [22] [23] LPS, a pro-inflammatory mediator and constituent of Gram-negative bacterial cell wall, directly disrupts macro-and microvascular EC barrier function in vitro and in vivo. 20, 24, 25 LPS primarily acts through the activation of toll-like receptor 4 (TLR4 31 Specifically, the injury elicited is characterized by neutrophil infiltration into the lung in association with increased inflammatory mediators including TNFα and NF-kB. 31 Thrombin is a serine protease generated by injured endothelial cells by the cleavage of circulating prothrombin, participating in the prothrombinase complex which also contains factors X and V, Ca 2+ and membrane phospholipids. 32 Thrombin not only induces coagulation, but also affects endothelial barrier function by releasing of inflammatory mediators and growth factors as well as inducing leukocyte adhesion on EC surface. 33 The cellular responses of EC to thrombin are mainly mediated through a thrombin-specific protease-activated receptor, PAR1. 34, 35 36 In vitro, thrombin produces rapid, reversible, concentration-dependent increases in EC permeability as measured by the clearance rate of Evans blue dye-labeled albumin across EC monolayers 37, 38 or by changes in transendothelial electrical resistance. 21, 39, 40 Thrombin infusion in animals resembles that seen after LPS administration in several respects, including pulmonary hypertension and increased pulmonary vascular permeability. 41, 42 Interestingly, thrombin inhibitor, anti-thrombin III (AT III) prevents LPS-induced pulmonary vascular injury suggesting the involvement of thrombin in LPS-induced permeability response.
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Contractile mechanisms of EC permeability. Endothelial barrier integrity is maintained by the precisely regulated balance between actomyosin contractile forces and adhesive cellcell, cell-matrix tethering forces. 4 Both competing forces are generated by the cytoskeleton comprising actin microfilaments, microtubules and intermediate filaments. 3, 4 Therefore, the A c c e p t e d M a n u s c r i p t kinase (MLCK) that phosphorylates MLC and, consequently, actomyosin interaction and cell contraction will be evoked. 47, 48 Beside the Ca 2+ /CaM-induced activation, endothelial (nonmuscle) MLCK can be activated by Src-mediated Tyr phosphorylation on its unique Nterminal fragment, which is absent in smooth muscle (SM) MLCK. 49 Thrombin was shown to increase EC permeability in a Src/MLCK-dependent manner via MLC-mediated contractile mechanism. 37, 50 Additionally, thrombin and LPS induced MLC-mediated EC contractile response and permeability via activation of Rho signaling pathway. 21, 29 The Ras homologous small GTPase Rho acts as molecular switch, cycling between an active GTP-bound and inactive GDP-bound state. 51 Rho activity is positively regulated by guanosine nucleotide exchange factors (GEFs) and inhibited by GTPase-activating proteins (GAPs), and GDP-dissociation inhibitors (GDIs). 52 Thrombin induced Rho activation involved G 12/13 -mediated activation of p115RhoGEF, GEF-H1 activation, as well as PKC-mediated inhibition of GDI-1. 76 In contrary, depletion of HSP-27 did not prevent p38-mediated TGFβ-induced EC barrier dysfunction. 83 Therefore, the exact cytoskeletal targets of p38 MAPK in endothelium remain undetermined. The putative targets include ezrin/radixin/moesin (ERM) proteins, which may be phosphorylated through p38-dependent mechanisms, 84 but apparently, the role of ERM phosphorylation in EC barrier regulation is agonist-specific. [84] [85] [86] [87] A few studies implicated the involvement of p38 activity in the activation of Rho/Rho kinase pathway and EC barrier dysfunction induced by TGFβ and
Staphylococcus aureus-derived toxins. 83, 88 In contrast, inhibition of p38 has no effect on thrombin-induced MLC phosphorylation, which involves Rho activation. 21, 73 Finally, recent A c c e p t e d M a n u s c r i p t 9 study supports the cross-talk between p38 and Rho pathways in the regulation of microvascular permeability.
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Crosstalk between microtubules and microfilaments in EC permeability regulation. In the thrombin model of EC permeability microtubule disassembly precedes actin stress fiber formation. 96 Thrombin may induce microtubule dissolution via stimulation of G 12/13 /p115RhoGEF cascade, followed by Rho/Rho kinase activation, resulting in phosphorylation of the microtubule-associated protein, tau. 93 In its unphosphorylated form, tau promotes assembly of microtubules and inhibits the rate of depolymerization.
97-99
Phosphorylation of tau decreases its capacity to bind microtubules and promotes MT assembly. 99, 100 Interestingly, p38 MAPK is also able to phosphorylate tau in vitro.
A c c e p t e d M a n u s c r i p t 10 in MT destabilization via tau phosphorylation.
Thrombin may also destabilize microtubules via Rho kinase-mediated phosphorylation and activation of LIM kinase (LIMK). 103 In quiescent conditions, LIM kinase is associated with microtubules. Thrombin treatment or ectopic expression of Rho kinase leads to dissociation of LIM kinase from microtubules accompanied by MT destabilization, phosphorylation/inhibition of cofilin, an actin depolymerization factor, resulting in F-actin assembly. 103 It was also recently reported that thrombin may destabilize microtubules via dephosphorylation of stathmin, a MT-associated protein, which in its phosphorylated form stabilizes the microtubules. 104 However, the thrombin-induced phosphatase, which is able to dephosphorylate stathmin and is involved in thrombin-induced permeability increase, is not known yet.
Thrombin-induced microtubule dissolution may further activate Rho pathway via GEF-H1, which has been recently characterized as a Rho-specific GEF localizing on microtubules. 105 In its MT-bound state, GEF-H1 is inactive, whereas GEF-H1 release caused by MT disassembly stimulates its activity towards Rho. 106 Importantly, GEF-H1 is directly involved in thrombin-induced permeability increase. 53 Microtubule dissolution may also affect cellular localization and activity of cytoskeletal regulatory proteins like CaD, which can be involved in EC barrier regulation. CaD co-purifies with microtubules from brain and potentiates tubulin polymerization. A c c e p t e d M a n u s c r i p t cells in a Ca 2+ -dependent manner. 111 The extracellular region contains five repeating domains which coordinate with calcium ions and form a rod-like structure. The intracellular tail of VEcadherin has two domains, the juxtamembrane domain (JMD) and the C-terminal domain (CTD). JMD binds p120 catenin, while CTD binds -catenin or plakoglobin (γ-catenin) which attach α-catenin to link the cadherin-catenin complex to the actin cytoskeleton. α-catenin also interacts with other actin-binding proteins, specifically, α-actinin, vinculin, TJ zonula occludin proteins: ZO-1, ZO-2, ZO-3 and possibly spectrin. VE-cadherin is critical for the proper assembly of AJs, and for normal endothelial barrier function. 112 VE-cadherin impairing results in interstitial edema and inflammation in lung and heart microvasculature. 113 Catenins also play an important role in the regulation of AJ assembly. -catenin has a dual role in cells. First it was identified as a component of AJs in the late '80s. Kemler and colleagues were able to isolate -catenin together with α-catenin and plakoglobin. 114 Later genetic and embryogenic studies revealed -catenin as a component of the Wnt signaling pathway playing an important role in embryonic development and tumorogenesis. 115 Recent study implicates the involvement of Wnt signaling in EC barrier regulation. 116 Plakoglobin plays an important role in cadherin/catenin complex assembly, as a linker between this complex and F-actin cytoskeleton. 117 Plakoglobin is an intracellular binding partner for VE-cadherin in ECs and its main function is to stabilize the AJ complex. 117, 118 Through α-catenin, plakoglobin is in connection with actin-binding proteins, like α-actinin and ZO-1. 119 Plakoglobin is closely related to β-catenin, sharing 80% sequence identity 120 and can bind the cytoplasmic domains of the classical cadherins. Both -catenin and plakoglobin were shown to stabilize the linkage between VE-cadherin and the actin cytoskeleton, thus regulating endothelial barrier function. 10 Thrombin-induced release of β-catenin and p120
catenin from the cell membrane has been described recently in human endothelium. and vascular endothelial growth factor induced tyrosine phosphorylation of VE-cadherin, -catenin and p120 thus increasing endothelial barrier permeability. 123 126 The cytoplasmic domain of VE-cadherin is phosphorylated at Ser 684,-686,-692 creating more interaction sites for -catenin binding. 111 Huber and Weis identified two residues in cadherin (Ser 684 and Ser 699 ) which are phosphorylated by casein kinase 2 (CK-2) and glycogen synthase kinase 3 (GSK-3). This phosphorylation of cadherin could stabilize and strengthen the catenin-cadherin complex by several hundred folds. 111, 127, 128 However, there are some reports indicating that cadherin phosphorylation can be a negative factor for binding to -catenin. 129 E-cadherin phosphorylation mediated by CK-2 leads to the disruption of AJs in keratinocytes. 130, 131 Multiple kinases are involved in β-catenin phosphorylation such as casein kinase I (CK-I) and GSK-3β. 132, 133 These kinases induce the phosphorylation of β-catenin on Ser 33/37 and Thr 41 , respectively, leading to its ubiquitination and proteosomal degradation. 132, 133 Wnt and other stimuli lead to the inactivation of GSK-3, thus decreasing -catenin phosphorylation, translocation into the nucleus and binding to transcription factors. 115 In contrary, Ser TJs regulate the transport of ions and solutes through the paracellular pathway. 136 They comprise of two families of transmembrane proteins, occludins and claudins as well as their cytoplasmic partners, zonula occludens (ZO) proteins, which connect TJs to actin cytoskeleton. 137 Compared to AJs, mechanisms regulating TJs are far less understood. AJs assembly precedes tight junction formation and in some in vivo cases cadherin is required for the formation of TJs, as it controls the recruitment of ZO-1 to TJ complexes. 138 Up-regulation of EC-specific claudin-5 isoform is involved in EC barrier enhancement in some, but not all models. 139, 140 Conversely, edemagenic agonists decreased claudin-5 and ZO-1 expression accompanied by translocation of ZO-1 from the cytoskeleton to the membrane/nuclear fractions. 141, 142 Recent study implicated the involvement of PKCε/Erk1/2 MAPK axis in phosphorylation of ZO-1 at Thr 770/772 . 143 This phosphorylation is accompanied by dissociation of ZO-1 from occludin resulting in EC barrier dysfunction. 143 In contrary, cyclic-straininduced enhancement of EC barrier function involved increased PKC-dependent ZO-1-occludin association. 144 In addition, Tyr phosphorylation of ZO-2 is involved in its dissociation from TJs and barrier dysfunction. EC demonstrated that the expression of TJ protein, connexin 43, is involved in LPS-induced permeability increase. 146 Consistent with these observations, connexin 43 inhibition blocked thrombin-induced permeability increase in lung capillaries. 147 In contrary, other report demonstrated that thrombin-induced permeability is accompanied by internalization (inhibition) of TJ communications in vascular endothelium. 148 Further studies are needed to define the involvement of TJ in the EC permeability regulation. 
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